Thangam Venkatesan, MD
Gastroenterology · Columbus, OHNPI 1710939384
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,698 of the $17,582 with a category attached, or 89.3%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 66.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $11,438 and has fallen 98.5% since, to $167 in 2024.
Across 16 payments — averaging $1098.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Alnylam Pharmaceuticals Inc.$6K
- Medtronic$57
Across 23 payments — averaging $31,944 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$658K
- Alnylam Pharmaceuticals Inc.$77K
What the payments were for
- Consulting fees$15,69889%
- Grants$570%
- Travel & lodging$1,4448%
- Food & beverage$3832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $11,672 |
| Alnylam Pharmaceuticals Inc. | 8 | $5,853 |
| Medtronic | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GIVLARRI$5,626
How this compares
$17,582 in reported general payments places this provider in the 85th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amitriptyline Hcl | 32 | $836 |
| Ondansetron OdtOndansetron | 24 | $314 |
| Nortriptyline Hcl | 22 | $221 |
| Topiramate | 11 | $28 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Columbus
- Tasos ManokasColumbus$411K
- Jeffrey LefkovitzColumbus$164K
- Adam HanjeColumbus$139K
- David LoColumbus$126K
- Shail GovaniColumbus$120K
- William SaltColumbus$87K
- Philip HartColumbus$58K
- Abdulfatah IssakColumbus$53K
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.